Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer

Use of gonadotropin-releasing hormone (GnRH) agonists has been widely adopted to provide reversible ovarian function suppression for pre-menopausal breast cancer patients who are also receiving aromatase inhibitor or tamoxifen therapy based on results of 25 randomized trials representing almost 15,0...

Full description

Saved in:
Bibliographic Details
Published in:NPJ breast cancer 2024-01, Vol.10 (1), p.8-8, Article 8
Main Authors: McCann, Kelly E., Goldfarb, Shari B., Traina, Tiffany A., Regan, Meredith M., Vidula, Neelima, Kaklamani, Virginia
Format: Article
Language:English
Subjects:
692/4028/67/1347
692/53/2423
Ablation
Biomarkers
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer Research
Cancer therapies
Cell Biology
Chemotherapy
Clinical trials
Endocrine therapy
Estrogens
Fertility
Follicles
Human Genetics
Laboratories
Medical research
Menopause
Oncology
Ovaries
Perspective
Pregnancy
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Use of gonadotropin-releasing hormone (GnRH) agonists has been widely adopted to provide reversible ovarian function suppression for pre-menopausal breast cancer patients who are also receiving aromatase inhibitor or tamoxifen therapy based on results of 25 randomized trials representing almost 15,000 women demonstrating a survival benefit with this approach. Past clinical trials designed to establish the efficacy of GnRH agonists have monitored testosterone in the prostate cancer setting and estradiol in the breast cancer setting. We explore the merits of various biomarkers including estradiol, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) and their utility for informing GnRH agonist treatment decisions in breast cancer. Estradiol remains our biomarker of choice in ensuring adequate ovarian function suppression with GnRH agonist therapy among pre-menopausal women with breast cancer. We recommend future trials to continue to focus on estradiol levels as the primary endpoint, as they have in the past.
ISSN:2374-4677
2374-4677
DOI:10.1038/s41523-024-00614-w